Search results for "HCV coinfection"

showing 4 items of 4 documents

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

2008

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis trea…

Liver CirrhosisMalePathologyCirrhosisAdult Antibodies; Viral; blood Carcinoma; Hepatocellular; blood/pathology/virology Cohort Studies Female Hepatitis B Core Antigens; immunology Hepatitis B virus; immunology Hepatitis C; blood/complications/pathology Humans Liver Cirrhosis; blood/etiology/pathology Liver Neoplasms; blood/pathology/virology Male Middle Aged Retrospective Studies Risk FactorsAntibodies ViralGastroenterologyanti HBcCohort StudiesimmunologyRisk FactorsHBVViralHCCCIRRHOSISLiver NeoplasmsGastroenterologyvirus diseasesHBV HCV COINFECTIONMiddle AgedHepatitis B Core AntigensHepatitis CAdult; Antibodies Viral; Carcinoma Hepatocellular; Cohort Studies; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; GastroenterologyHepatocellular carcinomaHCVFemaleAdultmedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularblood/pathology/virologyAntibodiesbloodblood/complications/pathologyInternal medicinemedicineHumansIn patientHEPATOCELLULAR CARCINOMAHEPATOCELLULAR CARCINOMA; HCV; HBV; CIRRHOSIS; HBV HCV COINFECTIONRetrospective StudiesHepatologybusiness.industryCarcinomaCancerHepatocellularmedicine.diseasedigestive system diseasesblood/etiology/pathologybusiness
researchProduct

Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease

2019

In Press.

Variceal bleedingTransient elastographyBaveno VI criteria; HCV coinfection; esophagogastroduodenoscopy; transient elastography; variceal bleedingesophagogastroduodenoscopyBaveno VI criteriaHCV coinfectionvariceal bleedingEsophagogastroduodenoscopytransient elastography
researchProduct